ArticleAnnals of medicine2026
Prediction of high-risk factor in early-stage lung cancer: micropapillary adenocarcinoma.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify independent risk factors for micropapillary adenocarcinoma (MPA) in lung adenocarcinoma, a subtype often associated with poor prognosis, in order to support preoperative risk assessment and treatment planning.
methodsPatients diagnosed with lung adenocarcinoma were classified into the micropapillary adenocarcinoma (MPA) group or the non-MPA group based on pathological findings. Clinical, pathological, and imaging data were collected for both groups. Patients were followed up through outpatient visits or telephone interviews. The primary outcome was disease-free survival (DFS). Independent risk factors for MPA were identified using univariate and multivariate logistic regression analyses. A preoperative predictive model and corresponding nomogram were developed. The receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value and the Hosmer-Lemeshow test and bootstrap - corrected calibration curves were used to evaluate the model's predictive performance.
resultsThe recurrence rate was significantly higher in the MPA group compared to the non-MPA group. Independent risk factors for MPA included smoking history, CT-diameter (≥22.5 mm), partially-solid nodule (PSN), solid nodule (SN), lobulation, spiculation, presence of vacuoles, and volume doubling time (VDT) (≤310 days). Guided by the multivariable analysis, we constructed a clinically oriented nomogram to provide an intuitive and practical tool for predicting MPA. The nomogram demonstrated excellent discrimination for predicting MPA, with an area under the ROC curve (AUC) of 0.923.
conclusionMPA predicts worse prognosis. The developed nomogram provides improved stratification of patients and supports informed clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.